The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
Pharmaceutical Technology on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
At JPM26, MSD noted it was awaiting 20 potential launches and 80 late-stage readouts, which it claims could double $35bn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback